A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Exclusion Criteria

• •Received small-molecule chemotherapy or targeted therapy within 2 weeks or 5 half-lives prior to the first dose
• •Received treatment with an anticancer biological therapy within 4 weeks prior to the first dose
• •Underwent major surgery within 4 weeks prior to the first dose
• •Has previously received treatment with a PARG inhibitor
• •Inadequate response to previous PARP inhibitor maintenance therapy
• •With central nervous system metastases
• •Patients with clinically significant cardiovascular or cerebrovascular diseases
• •Uncontrolled active infections requiring intravenous antibiotics or hospitalization
• •Adverse reactions from prior anticancer therapy have not yet resolved to a grade ≤1